Clinical Care Options - Oncology CME - The Right Care for the Younger Patient: Meeting the Needs of Adolescents and Young Adults With Cancer

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the physical and psychosocial challenges facing the AYA cancer patient
• Suggest the most suitable treatment strategy for individual AYA patients with cancer based on current evidence
• Apply current evidence to select treatment centers (adult or pediatric) that optimize treatment for AYA patients

Clinical Care Options - Oncology CME - An Update on Metastatic Breast Cancer

Clinical Care Options - Oncology CME - An Update on Early Breast Cancer

Clinical Care Options website: update includes Avastin - Ovarian Cancer

Note: full free access (requires free registration)

Authors: Maurie Markman, MD

Released: 11/17/10

Last Reviewed: 12/2/10 (What's New)

• Introduction
• BRCA Mutations in Ovarian Cancer
• Screening for Ovarian Cancer
• Symptoms of Ovarian Cancer
• Surgical Staging of Ovarian Cancer
• Primary Surgical Cytoreduction in Ovarian Cancer
• Interval Surgical Cytoreduction and Neoadjuvant Chemotherapy
• Chemotherapy for High-Risk Early-Stage Ovarian Cancer
• Primary Chemotherapy of Advanced Stage Ovarian Cancer
  • Intraperitoneal Chemotherapy of Small-Volume Residual Ovarian Cancer
  • Maintenance Therapy of Advanced Ovarian Cancer
• Second-Line Therapy of Ovarian Cancer
• Platinum-Sensitive vs Platinum-Resistant Recurrent Ovarian Cancer
• Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
• Treatment of Platinum-Resistant Ovarian Cancer
• Intermediate Platinum Sensitivity
• Carboplatin Hypersensitivity Reactions
• Other Management Options in Recurrent/Resistant Ovarian Cancer
• Future Research Directions in Ovarian Cancer
• Tables and Figures
• References

Clinical Care Options Oncology - Truth and Consequences: Antiangiogenic Therapies in Cancer

.

CCO Treatment Updates Truth and Consequences: Antiangiogenic Therapies in Cancer Virtual Presentation Truth and Consequences: Antiangiogenic Therapies in Cancer Faculty: Robert S. Kerbel, PhD Release Date: July 02, 2010 Expiration Date: July 01, 2011 Robert S. Kerbel, PhD, reviews the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Learning Objectives Upon completion of this activity, participants should be able to: Describe the mechanisms of targeting angiogenesis Explain the mechanisms of resistance to antiangiogenic drugs Describe the phenomenon of rebound or tumor flare that may result from the discontinuation of antiangiogenic therapy Evaluate data supporting the use of angiogenesis inhibitors in the neoadjuvant, adjuvant, and metastatic settings Assess the potential clinical role of biomarkers of response to antiangiogenic therapy Truth and Consequences: Antiangiogenic Therapies in Cancer Download slides on the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Format: Microsoft PowerPoint (.ppt) | File size: 8.61 MB | Date posted: 7/2/2010 . Jointly Sponsored by USF Health and Clinical Care Options, LLC.

Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer

Note: registration required to view (free) SPECIAL EDITION / EDUCATIONAL REVIEWS

ISSUE: AUGUST, 2010 | VOLUME: 05:08 Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer

full free access: Clinical Care Options Oncology - Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer (slides)

>

Clinical Care Options database - inPractice

Note: no sign on required/searchable database
Jointly sponsored by USF Health and Clinical Care Options, LLC:
Use inPractice’s search to quickly access answers to your point-of-care questions. inPractice searches the following resources at the same time:

• HIV inPractice
• Oncology inPractice
• Drug Information

• Guidelines
• PubMed
• CCO CME/CE

Clinical Care Options - CME - Dr Maurie Markman updated CME March 3, 2010

Note: requires Password/Registration (free):

Oncology - Ovarian Cancer
Authors: Maurie Markman, MD
Date Released: October 01, 2009
Last Updated: March 03, 2010

Table of Contents

• Ovarian Cancer
  • Introduction
  • BRCA Mutations in Ovarian Cancer
  • Screening for Ovarian Cancer
  • Symptoms of Ovarian Cancer
  • Surgical Staging of Ovarian Cancer
  • Primary Surgical Cytoreduction in Ovarian Cancer
  • Interval Surgical Cytoreduction and Neoadjuvant Chemotherapy
  • Chemotherapy for High-Risk Early-Stage Ovarian Cancer
  • Primary Chemotherapy of Advanced Stage Ovarian Cancer
    • Intraperitoneal Chemotherapy of Small-Volume Residual Ovarian Cancer
    • Maintenance Therapy of Advanced Ovarian Cancer
  • Second-Line Therapy of Ovarian Cancer
  • Platinum-Sensitive vs Platinum-Resistant Recurrent Ovarian Cancer
  • Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
  • Treatment of Platinum-Resistant Ovarian Cancer
  • Intermediate Platinum Sensitivity
  • Carboplatin Hypersensitivity Reactions
  • Other Management Options in Recurrent/Resistant Ovarian Cancer
  • Future Research Directions in Ovarian Cancer
  • Tables and Figures
  • References